## The PD-1/PD-L1 Pathway as a Target in Tumor Immunotherapy

Scott S. Tykodi, MD, PhD December 14, 2013





Fred Hutchinson Cancer Research Center UW Medicine Seattle Children's

# **Learning Objectives**

- Review the biology of the PD-1 / PD-L1 pathway as it relates to tumor immunity
- Review safety and efficacy data for the lead therapeutic blocking antibodies targeting PD-1 and PD-L1
  - Anti-PD-1 (nivolumab)
  - Anti-PD-L1 (MPDL3280A)
- Discuss available evidence for on-target mechanism of action and biomarker development.

## T Cell Specificity: TCR Recognition of HLA + Antigenic Peptide





**HLA Class I** 

#### HLA Class II


HLA-Associated Peptide Antigens

Normal cell proteins

 Tumor-specific mutated proteins –
 *"the mutanome"*


 Tumor-associated viral proteins

#### PD-1/PD-L1 Blockade: An Emerging Strategy for Cancer Immunotherapy




Keir, ME et al. Annu Rev Immunol (2008) 26:677. Pardoll, DM. Nat Rev Cancer (2012) 12:252.

#### **CTLA-4 vs PD-1: Distinct Immune Checkpoints**




## Immune Checkpoint Function Revealed by Murine Knockout Studies



Waterhouse, P *et al*. <u>Science</u> (1995) 270:985. Tivol, EA *et al*. <u>Immunity</u> (1995) 3:541. Nishimura, H *et al*. <u>Immunity</u> (1999) 11:141. Nishimura, H *et al*. <u>Science</u> (2001) 291:319. Latchman, YE *et al*. <u>PNAS</u> (2004) 101:10691.

## **PD-1/PD-L1 Binding Interactions**



#### PD-L1 (B7-H1, CD274)


- Constitutive Expression
  - Macrophage, DC, B-cell, ?T-cell
- IFN-γ Inducible
- Tumor, normal epithelium

## PD-L1 Expression is Common in Solid and Hematopoietic Tumors

Cancer Type	Histology	% PD-L1 <sup>+</sup> Tumors
Solid Tumors	Melanoma	40-100
	NSCLC	35-95
	RCC	15-24
	CRC	53
	Gastric	42
	Ovarian cancer	33-80
	Pancreatic	39
	Breast	31-34
	НСС	45-93
	Urothelial carcinoma	28-100
Hematologic Tumors	Multiple Myeloma	93
	Lymphomas	17-94
	Leukemias	11-42

Adapted from Chen, DS et al. Clin Ca Res (2012) 18:6580.


## Association of Tumor B7-H1 (PD-L1) Expression with Death from ccRCC



In multivariate analysis, PD-L1 expression (≥ 5%) on RCC tumor cells was an independent risk factor for death


Thompson, RH et al. Cancer Res (2006) 66:3381-3385.

## Strong Association of PD-L1 Expression in Melanoma with Immune Cell Infiltration



- PD-L1 and TIL co-localize
- TIL may trigger their own inhibition by IFN-γ mediated PD-L1 induction


Metastatic Melanoma (N=53)



PD-L1 expression (≥ 5%) on melanocytes was positively associated with survival

Taube, JM et al. Sci Transl Med (2012) 4:ra37.

# Tumor Immune Escape by "Adaptive Resistance"



**Adaptive Immune Resistance** 

Taube, JM et al. Sci Transl Med (2012) 4:ra37.

### **PD-1 Targeted Drugs in Development 2013**

#### PD-1 Blockade

Drug	Developer	Composition	Development Phase
Nivolumab (BMS-936558)	Bristol-Myers Squibb	fully human IgG4 mAb	phase III
MK-3475	Merck	humanized IgG4 mAb	phase III
CT-011	CureTech / Teva	humanized IgG1 mAb	phase II
AMP-224	Amplimmune / GlaxoSmithKline	PD-L2 / IgG1 fusion protein	phase I

Abbreviations: mAb - monoclonal antibody


## Anti-PD1 Monoclonal Antibody Nivolumab (BMS-936558, MDX-1106)

- Fully human IgG4 anti-human PD-1-blocking Ab
- No known Fc function (ADCC, CDC)
- High affinity for PD-1 (K<sub>D</sub> ~3 nM)
- Preliminary results of a phase Ib dose-escalation study with nivolumab published June 2012
- 296 patients in total with melanoma, RCC, NSCLC, colorectal cancer, or prostate cancer




Topalian, SL *et al*. <u>New Engl J Med</u> (2012) 366:2443

#### Nivolumab Study Design: Phase Ib Multi-dose Regimen



# PD-1-receptor occupancy by anti-PD-1 antibody



Topalian, SL et al. <u>New Engl J Med</u> (2012) 366:2443

## Clinical Activity of Nivolumab in 236 Patients; (All Doses)

Tumor Type		Patients	ORR (%)	SD ≥24 weeks (%)	PFSR at 24 Weeks (%)
Melano	ma	94	28	6	41
NSCLC	Squamous	18	33	0	33
	Nonsquamous	56	12	9	22
RCC		33	27	27	56


• ORR was assessed using modified RECIST v1.0 criteria

ORR = objective response rate; PFSR = progression-free survival rate; SD = stable disease

 8 additional pts with reduction in tumor measurements, but in presence of new lesions – Immune related response pattern

Topalian, SL et al. <u>New Engl J Med</u> (2012) 366:2443

#### **Changes in Melanoma Tumor Burden with Nivolumab Treatment**



Topalian, SL et al. New Engl J Med (2012) 366:2443

#### Immune-related Adverse Events (irAE) Associated with Nivolumab (anti-PD1)

Adverse Event	Any Event (%)	Grade 3/4 (%)
Any	41	6
Dermatologic Prutitis Rash	21	1
Gastrointestinal Diarrhea	11	1
Hepatic	4	1
Endocrine Hypothyroid Hypophysitis Adrenal insufficiency	3	1
Pulmonary	3	1*

- Data from 296 pts (all histologies entered on phase Ib study)
- \*Includes 3 deaths from pneumonitis

Topalian, SL *et al*. <u>New Engl J Med</u> (2012) 366:2443

#### **PD-L1 Targeted Drugs in Development 2013**

#### PD-L1 Blockade

Drug	Developer	Composition	Development Phase
MPDL3280A (RG7446)	Genetech	IgG1 mAb with a modified Fc domain	phase II
BMS-936559	Bristol-Myers Squibb	fully human IgG4 mAb	phase I
MEDI4736	MedImmune / AstraZeneca	fully human mAb	phase I

Abbreviations: mAb - monoclonal antibody

## MPDL3280A: Anti-PD-L1

- IgG1 anti-human PD-L1 blocking Ab
- Fc domain engineered to remove ADCC function and avoid killing activated T cells
- Inhibits PD-L1 binding to PD-1 or B7-1 in vitro

### MPDL3280A - Phase Ia Experience (N=171)

- Administered iv q3 weeks x maximum of 16 doses (~ 1 yr)
- Doses ranging from 0.01 mg/kg to 20 mg/kg;
  (162/171 patients treated at doses ≥ 3mg/kg)
- Primary Objectives:
  - Evaluate safety and tolerability
  - Determine MTD and recommended phase II dose

Tumor Type	N (Total = 171)
Melanoma	44 (26%)
RCC	55 (32%)
NSCLC	52 (30%)
<b>Other</b> 10 histologies included CRC (4), gastric	20 (12%)

### MPDL3280A Efficacy Summary (N=140)

Tumor Type	Patients (%)		SD ≥24 weeks (%)	PFSR at 24 Weeks (%)
Melanoma	38	29	5	43
NSCLC	41	22	12	46
RCC	47	13	32	53


- ORR was assessed using modified RECIST v1.1 criteria
- ORR = objective response rate; PFSR = progression-free survival rate; SD = stable disease
- Additional delayed responses not reflected in ORR
- Other responses included CRC (PR 1/4) and gastric (PR in 1/1)

### MPDL3280A Phase Ia Safety – Immune-related AE

Adverse Event	Grade 3/4 N (%)
Any	4 (2)
Dermatologic Prutitis Rash	0
Gastrointestinal Diarrhea	1 (0)
Hepatic	2 (1)
Endocrine Hyperglycemia	1 (0)
Pulmonary	0*

- No Treatment related deaths
- No Grade 3-5 pneumonitis
- No MTD identified at doses tested

#### **Correlation of PD-L1 Expression in Pretreatment Tumor Biopsies with Responses to Nivolumab**




Topalian, SL *et al*. <u>New Engl J Med</u> (2012) 366:2443

## MPDL3280A Phase Ia: Response by PD-L1 IHC Status (N=103/140)

.1 Positive % (13/36)	PD-L1 Negative 13% (9/67)	All† 21% (29/140)
% (13/36)	13% (9/67)	21% (29/140)
	28 13 Iting immune cells th	41 20 at stain for
X	,	33 13 with infiltrating immune cells the IHC

#### PD-1 Blockade: Increased CD8+ T Cells in a Regressing Melanoma Tumor Treated with Nivolumab



## MPDL3280A Phase Ia: PD-L1 IHC Status in Paired Tumor Biopsies

Summary of responses to MPDL3280A in paired biopsies

Max SLD Decrease*	Increase in tumor PD-L1 <sup>†</sup>
> 30% reduction	4/4 (100%)
Unevaluable SLD (due to tumor excision <sup>®</sup> )	2/2 (100%)
0-30% reduction	2/6 (33%)
0-20% increase	1/10 (10%)
> 20 increase	0/4 (0%)

\* Best response; SLD = sum of linear dimensions.

- <sup>+</sup> PD-L1 expression measured by proprietary Genetech/Roche IHC Assay for PD-L1 expression on infiltrating immune cells.
- I Excision of responding tumor for marker analysis. Patient not evaluable for max SLD change.

Powderly, JD *et al*. <u>JCO</u> (2013) 31:abstr 3001.

## Anti-PD1/PDL1 Cancer Immunotherapy: Summary and Conclusions

- Spontaneous and durable anti-tumor effects in a subset of patients with continuous treatment (q 2-3 weeks)
- Similar efficacy with PD-1 versus PD-L1 blockade
- Side effects are autoimmune in nature
  - Manageable in early testing
  - Similar spectrum of autoimmune phenomena with PD1 vs CTLA4
  - \*frequency and severity of pneumonitis worse with PD1 vs CTLA4 blockade
- Ongoing evaluation of the association of pretreatment tumor expression of PD-L1 with clinical outcome.

## **Advanced Phase Clinical Trials Pipeline for Anti-PD1/PDL1 Therapies**

Target	Diagnosis	Phase	Drug and Format
	PD-1 NSCLC III RCC III	111	Nivolumab- 1L vs Ipi or Combo- 1L vs dacarbazine- ≥ 2L vs chemo (Ipi +/- BRAF failure)
			MK-3475 - 1L vs Ipi
PD-1		111	Nivolumab - 2L vs standard chemo (SSC and non- SSC)
			MK-3475 - 2L vs chemo
			Nivolumab - 2L randomized vs everolimus
PD-L1	NSCLC Melanoma (RCC)	II	MPDL3280A - (multiple studies)

www.clinicaltrials.gov